HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway

Journal of Immunology

Volumn 180, Issue 4, 2008, Pages 2357-2366

  Jindra, Peter T ^a   Jin, Yi Ping ^a   Rozengurt, Enquire ^a   Reed, Elaine F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; HLA ANTIBODY; HLA ANTIGEN CLASS 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN BCL 2; PROTEIN KINASE B; RAPAMYCIN; RAPAMYCIN INSENSITIVE COMPANION OF MAMMALIAN TARGET OF RAPAMYCIN; REGULATORY ASSOCIATED PROTEIN OF MAMMALIAN TARGET OF RAPAMYCIN; SERINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ALLOANTIBODY; HLA ANTIGEN; MTORC1 PROTEIN, HUMAN; PROTEIN KINASE; TRANSCRIPTION FACTOR;

ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; COMPLEX FORMATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE FUNCTION; HUMAN; HUMAN CELL; LONG TERM EXPOSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; UPREGULATION; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; GENETICS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; ISOANTIBODIES; PROTEIN KINASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 40849138320     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.4.2357     Document Type: Article

References (48)

1. Azuma, H., and N. L. Tilney. 1994. Chronic graft rejection. Curr. Opin. Immunol. 6: 770-776.
2. Terasaki, P. I., and J. Cai. 2005. Humoral theory of transplantation: further evidence. Curr. Opin. Immunol. 17: 541-545.
3. Michaels, P. J., M. C. Fishbein, and R. B. Colvin. 2003. Humoral rejection of human organ transplants. Springer Semin. Immunopathol. 25: 119-140.
4. Costa, A. N., M. P. Scolari, S. Iannelli, A. Buscaroli, G. L. D'Arcangelo, B. Brando, F. Indiveri, M. Savi, L. C. Borgnino, L. B. DeSanctis, et al. 1997. The presence of posttransplant HLA-specific IgG antibodies detected by enzyme-linked immunosorbent assay correlates with specific rejection pathologies. Transplantation 63: 167-169.
5. Soleimani, B., R. I. Lechler, P. I. Hornick, and A. J. George. 2006. Role of alloantibodies in the pathogenesis of graft arteriosclerosis in cardiac transplantation. Am. J. Transplant. 6: 1781-1785.
6. Uehara, S., C. M. Chase, L. D. Cornell, J. C. Madsen, P. S. Russell, and R. B. Colvin. 2007. Chronic cardiac transplant arteriopathy in mice: relationship of alloantibody, C4d deposition and neointimal fibrosis. Am. J. Transplant. 7: 57-65.
7. Soleimani, B., A. Katopodis, G. Wieczorek, A. J. George, P. I. Hornick, and C. Heusser. 2006. Smooth muscle cell proliferation but not neointimal formation is dependent on alloantibody in a murine model of intimal hyperplasia. Clin. Exp. Immunol. 146: 509-517.
8. Maruyama, T., A. Jaramillo, K. Narayanan, T. Higuchi, and T. Mohanakumar. 2005. Induction of obliterative airway disease by anti-HLA class I antibodies. Am. J. Transplant. 5: 2126-2134.
9. Reed, E. F. 2003. Signal transduction via MHC class I molecules in endothelial and smooth muscle cells. Crit. Rev. Immunol. 23: 109-128.
10. Jindra, P. T., X. Zhang, A. Mulder, F. Claas, J. Veale, Y. P. Jin, and E. F. Reed. 2006. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation 82: S33-S35.
11. Lepin, E. J., Y. P. Jin, S. P. Barwe, E. Rozengurt, and E. F. Reed. 2004. HLA class I signal transduction is dependent on Rho GTPase and ROK. Biochem. Biophys. Res. Commun. 323: 213-217.
12. Coupel, S., F. Leboeuf, G. Boulday, J. P. Soulillou, and B. Charreau. 2004. RhoA activation mediates phosphatidylinositol 3-kinase-dependent proliferation of human vascular endothelial cells: an alloimmune mechanism of chronic allograft nephropathy. J. Am. Soc. Nephrol. 15: 2429-2439.
13. Jin, Y. P., R. P. Singh, Z. Y. Du, A. K. Rajasekaran, E. Rozengurt, and E. F. Reed. 2002. Ligation of HLA class I molecules on endothelial cells induces phosphorylation of Src, paxillin, and focal adhesion kinase in an actin-dependent manner. J. Immunol. 168: 5415-5423.
14. Jin, Y. P., Y. Korin, X. Zhang, P. T. Jindra, E. Rozengurt, and E. F. Reed. 2007. RNA interference elucidates the role of focal adhesion kinase in HLA class I-mediated focal adhesion complex formation and proliferation in human endothelial cells. J. Immunol. 178: 7911-7922.
15. Jin, Y. P., M. C. Fishbein, J. W. Said, P. T. Jindra, R. Rajalingam, E. Rozengurt, and E. F. Reed. 2004. Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum. Immunol. 65: 291-302.
16. Lepin, E. J., Q. Zhang, X. Zhang, P. T. Jindra, L. S. Hong, P. Ayele, M. V. Peralta, D. W. Gjertson, J. A. Kobashigawa, W. D. Wallace, et al. 2006. Phosphorylated S6 ribosomal protein: a novel biomarker of antibody-mediated rejection in heart allografts. Am. J. Transplant. 6: 1560-1571.
17. Kim, D. H., D. D. Sarbassov, S. M. Ali, J. E. King, R. R. Latek, H. Erdjument-Bromage, P. Tempst, and D. M. Sabatini. 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175.
18. Nojima, H., C. Tokunaga, S. Eguchi, N. Oshiro, S. Hidayat, K. Yoshino, K. Hara, N. Tanaka, J. Avruch, and K. Yonezawa. 2003. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J. Biol. Chem. 278: 15461-15464.
19. Hara, K., Y. Maruki, X. Long, K. Yoshino, N. Oshiro, S. Hidayat, C. Tokunaga, J. Avruch, and K. Yonezawa. 2002. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110: 177-189.
20. Sarbassov, D. D., S. M. Ali, D. H. Kim, D. A. Guertin, R. R. Latek, H. Erdjument-Bromage, P. Tempst, and D. M. Sabatini. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14: 1296-1302.
21. Sarbassov, D. D., D. A. Guertin, S. M. Ali, and D. M. Sabatini. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
22. Sarbassov, D. D., S. M. Ali, S. Sengupta, J. H. Sheen, P. P. Hsu, A. F. Bagley, A. L. Markhard, and D. M. Sabatini. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell. 22: 159-168.
23. Makino, C., Y. Sano, T. Shinagawa, J. B. Millar, and S. Ishii. 2006. Sin1 binds to both ATF-2 and p38 and enhances ATF-2-dependent transcription in an SAPK signaling pathway. Genes Cells 11: 1239-1251.
24. Yang, Q., K. Inoki, T. Ikenoue, and K. L. Guan. 2006. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev. 20: 2820-2832.
25. Pearce, L. R., X. Huang, J. Boudeau, R. Pawlowski, S. Wullschleger, M. Deak, A. Ibrahim, R. Gourlay, M. A. Magnuson, and D. R. Alessi. 2007. Identification of protor as a novel rictor-binding component of mTOR-complex-2. Biochem. J. 405: 513-522.
26. Yeh, M., N. Leitinger, R. de Martin, N. Onai, K. Matsushima, D. K. Vora, J. A. Berliner, and S. T. Reddy. 2001. Increased transcription of IL-8 in endothelial cells is differentially regulated by TNF-α and oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 21: 1585-1591.
27. Harris, P. E., H. Bian, and E. F. Reed. 1997. Induction of high affinity fibroblast growth factor receptor expression and proliferation in human endothelial cells by anti-HLA antibodies: a possible mechanism for transplant atherosclerosis. J. Immunol. 159: 5697-5704
28. Bian, H., and E. F. Reed. 1999. Alloantibody-mediated class I signal transduction in endothelial cells and smooth muscle cells: enhancement by IFN-γ and TNF-α. J. Immunol. 163: 1010-1018.
29. Hay, N., and N. Sonenberg. 2004. Upstream and downstream of mTOR. Genes Dev. 18: 1926-1945.
30. Jacinto, E., R. Loewith, A. Schmidt, S. Lin, M. A. Ruegg, A. Hall, and M. N. Hall. 2004. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell. Biol. 6: 1122-1128.
31. Hidalgo, M., and E. K. Rowinsky. 2000. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19: 6680-6686.
32. Dormond, O., J. C. Madsen, and D. M. Briscoe. 2007. The effects of mTOR-AKT interactions on anti-apoptotic signaling in vascular endothelial cells. J. Biol. Chem. 282: 23679-23686.
33. Narayanan, K., A. Jaramillo, D. L. Phelan, and T. Mohanakumar. 2004. Preexposure to sub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur. J. Immunol. 34: 2303-2312.
34. Westhoff, M. A., B. Serrels, V. J. Fincham, M. C. Frame, and N. O. Carragher. 2004. SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling. Mol. Cell. Biol. 24: 8113-8133.
35. Parsons, J. T., and S. J. Parsons. 1997. Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. Curr. Opin. Cell Biol. 9: 187-192.
36. Jiang, X., R. Jacamo, E. Zhukova, J. Sinnett-Smith, and E. Rozengurt. 2006. RNA interference reveals a differential role of FAK and Pyk2 in cell migration, leading edge formation, and increase in focal adhesions induced by LPA in intestinal epithelial cells. J. Cell. Physiol. 207: 816-828.
37. Li, W., M. Petrimpol, K. D. Molle, M. N. Hall, E. J. Battegay, and R. Humar. 2007. Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2. Circ. Res. 100: 79-87.
38. Guertin, D. A., D. M. Stevens, C. C. Thoreen, A. A. Burds, N. Y. Kalaany, J. Moffat, M. Brown, K. J. Fitzgerald, and D. M. Sabatini. 2006. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1. Dev. Cell 11: 859-871.
39. 473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 280: 40406-40416.
40. Bian, H., P. E. Harris, and E. F. Reed. 1998. Ligation of HLA class I molecules on smooth muscle cells with anti-HLA antibodies induces tyrosine phosphorylation, fibroblast growth factor receptor expression, and cell proliferation. Int. Immunol. 10: 1315-1323.
41. Hernandez-Negrete, I., J. Carretero-Ortega, H. Rosenfeldt, R. Hernandez-Garcia, J. V. Calderon-Salinas, G. Reyes-Cruz, J. S. Gutkind, and J. Vazquez-Prado. 2007. P-Rex1 links mTOR signaling to Rac activation and cell migration. J. Biol. Chem. 282: 23708-23715.
42. Huet, C., J. F. Ash, and S. J. Singer. 1980. The antibody-induced clustering and endocytosis of HLA antigens on cultured human fibroblasts. Cell 21: 429-438.
43. Ash, J. F., D. Louvard, and S. J. Singer. 1977. Antibody-induced linkages of plasma membrane proteins to intracellular actomyosin-containing filaments in cultured fibroblasts. Proc. Natl. Acad. Sci. USA 74: 5584-5588.
44. Mancini, D., S. Pinney, D. Burkhoff, J. LaManca, S. Itescu, E. Burke, N. Edwards, M. Oz, and A. R. Marks. 2003. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 108: 48-53.
45. Salama, A. D., A. Delikouras, C. D. Pusey, H. T. Cook, G. Bhangal, R. I. Lechler, and A. Dorling. 2001. Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. Am. J. Transplant. 1: 260-269.
46. Narayanan, K., M. D. Jendrisak, D. L. Phelan, and T. Mohanakumar. 2006. HLA class I antibody mediated accommodation of endothelial cells via the activation of PI3K/cAMP dependent PKA pathway. Transpl. Immunol. 15: 187-197.
47. Edinger, A. L., and C. B. Thompson. 2002. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell 13: 2276 -2288.
48. Jindra P. T., A. Hsuch, L. Hong, D. W. Gjertson, X.-D. Shen, F. Gao, J. Dang, P. S. Mischel, W. M. Baldwin 3rd, M. C. Fishbein, J. W. Kupiec-Weglinski, and E. F. Reed. 2008. Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J. Immunol. In press.